Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) has received an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.63.
A number of equities research analysts recently weighed in on APTO shares. Oppenheimer upped their target price on shares of Aptose Biosciences from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Tuesday, March 30th. Jonestrading started coverage on shares of Aptose Biosciences in a report on Monday, February 22nd. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, February 8th.
Shares of NASDAQ APTO traded down $0.38 during trading on Friday, hitting $5.25. 135,084 shares of the company traded hands, compared to its average volume of 4,150,043. The business’s fifty day moving average is $4.53 and its 200 day moving average is $4.90. Aptose Biosciences has a fifty-two week low of $3.39 and a fifty-two week high of $9.00. The firm has a market capitalization of $466.41 million, a price-to-earnings ratio of -8.20 and a beta of 1.62.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Monday, March 22nd. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Analysts expect that Aptose Biosciences will post -0.69 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of APTO. Raymond James & Associates increased its stake in Aptose Biosciences by 15.4% in the 3rd quarter. Raymond James & Associates now owns 30,050 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 4,000 shares during the last quarter. Morgan Stanley increased its stake in Aptose Biosciences by 38.2% in the 3rd quarter. Morgan Stanley now owns 466,030 shares of the biotechnology company’s stock valued at $2,796,000 after buying an additional 128,843 shares during the last quarter. Consonance Capital Management LP increased its stake in Aptose Biosciences by 14.7% in the 3rd quarter. Consonance Capital Management LP now owns 7,994,904 shares of the biotechnology company’s stock valued at $47,969,000 after buying an additional 1,025,000 shares during the last quarter. Polar Capital LLP increased its stake in Aptose Biosciences by 41.3% in the 3rd quarter. Polar Capital LLP now owns 1,805,417 shares of the biotechnology company’s stock valued at $10,833,000 after buying an additional 527,501 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Aptose Biosciences in the 3rd quarter valued at about $12,400,000. Hedge funds and other institutional investors own 52.22% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also: What is a portfolio manager?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.